Conditions: Type 2 Diabetes Mellitus
Keywords: TYpe 2 diabetes mellitus Newly diagnosed Beta-cell function
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 58
Healthy volunteers: no

Brief summary:
The study evaluates the rate beta-cell function decline in newly diagnosed type 2 diabetic patients on two different treatment regimens: insulin and metformin versus glyburide, metformin and pioglitazone.

Detailed description:
This is a 72 months long randomized clinical trial longitudinally evaluating beta-cell function, as well as glycemic control and inflammatory markers in newly diagnosed type 2 diabetic patients on two different treatment regimens: insulin and metformin versus glyburide, metformin and pioglitazone.

Arms:
arm 1: Metformin 1000mg/BID and Insulin Novolog 70/30 per protocol titration arm 2: Metformin 1000mg/BID, Pioglitazone 45 mg and glyburide per protocol titration

Interventions: intervention 1: Metformin intervention 2: Insulin intervention 3: Metfomin intervention 4: Pioglitazone intervention 5: glyburide
Intervention descriptions: intervention 1: Metformin 1000mg/BID intervention 2: Insulin Novolg 70/30 per protocol titration intervention 3: Metformin 1000mg/BID intervention 4: Pioglitazone 45mg intervention 5: Glyburide per protocol titration

Protocol document: